These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Hospitalization and Healthcare Resource Utilization of Omidubicel-Onlv versus Umbilical Cord Blood Transplantation for Hematologic Malignancies: Secondary Analysis from a Pivotal Phase 3 Clinical Trial. Majhail NS; Miller B; Dean R; Manghani R; Shin H; Sivaraman S; Maziarz RT Transplant Cell Ther; 2023 Dec; 29(12):749.e1-749.e5. PubMed ID: 37703995 [TBL] [Abstract][Full Text] [Related]
3. Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord Blood. Lin C; Sajeev G; Stiff PJ; Brunstein CG; Cutler C; Sanz G; Lindemans CA; Rezvani AR; Hanna R; Koh LP; Maziarz RT; Hwang WYK; Song Y; Liu Q; Manghani R; Sivaraman S; Signorovitch J; Horwitz ME; Sung AD Transplant Cell Ther; 2023 Jan; 29(1):52.e1-52.e9. PubMed ID: 36179986 [TBL] [Abstract][Full Text] [Related]
4. Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation. de Koning C; Tao W; Lacna A; van Veghel K; Horwitz ME; Sanz G; Jagasia MH; Wagner JE; Stiff PJ; Hanna R; Cilloni D; Valcárcel D; Peled T; Galamidi Cohen E; Goshen U; Pandit A; Lindemans CA; Jan Boelens J; Nierkens S Bone Marrow Transplant; 2021 Nov; 56(11):2826-2833. PubMed ID: 34312498 [TBL] [Abstract][Full Text] [Related]
5. Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Bejanyan N; Brunstein CG; Cao Q; Lazaryan A; Luo X; Curtsinger J; Mehta RS; Warlick E; Cooley SA; Blazar BR; Miller JS; Weisdorf D; Wagner JE; Verneris MR Blood Adv; 2018 Apr; 2(8):909-922. PubMed ID: 29678809 [TBL] [Abstract][Full Text] [Related]
6. The impact of omidubicel on immune reconstitution and infections in cord blood transplant patients. De Sa H; Maziarz RT; Gandhi AP Expert Opin Biol Ther; 2024 Mar; 24(3):139-146. PubMed ID: 38481366 [TBL] [Abstract][Full Text] [Related]
7. Projected Impact of Omidubicel-onlv on Racial/Ethnic Disparities in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Outcomes in Hematologic Malignancies. Khera N; Edwards ML; Song Y; Sun R; Manghani R; Shin H; Simantov R; Signorovitch J; Sivaraman S; Gergis U Adv Ther; 2024 Apr; 41(4):1637-1651. PubMed ID: 38427220 [TBL] [Abstract][Full Text] [Related]
20. Early Reconstitution of NK and γδ T Cells and Its Implication for the Design of Post-Transplant Immunotherapy. de Witte MA; Sarhan D; Davis Z; Felices M; Vallera DA; Hinderlie P; Curtsinger J; Cooley S; Wagner J; Kuball J; Miller JS Biol Blood Marrow Transplant; 2018 Jun; 24(6):1152-1162. PubMed ID: 29505821 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]